The Venture Fund With an Admissions Requirement: You Had to Go to Oxford
A Palo Alto fund turned an alumni network into an asset class - if your startup wants in, someone in the founding story has to have walked through an Oxford quad.
Most venture funds pitch you a thesis. A sector they love, a wave they are riding, a founder profile they claim to spot before anyone else. Oxonian Ventures pitches something older and stranger: a place. To get its money into your company, someone in your founding story has to have studied at the University of Oxford. That is the filter. Everything else - biotech, fintech, quantum computing, kombucha - flows from it.
It sounds like a members-only quirk, the kind of thing that photographs well at an alumni dinner and rarely writes a check. But the numbers argue otherwise. Since 2016 the fund has backed more than 30 early-stage companies, pooled capital from over 90 accredited Oxford-alumni investors, and in July 2024 announced the first close of a third fund targeting $15 million. Somewhere along the way, an alumni club grew into an actual venture firm.
What it doesAn alumni list, reimagined as deal flow
Oxonian Ventures is an early-stage venture fund based at 380 Hamilton Avenue in Palo Alto, a few blocks from the coffee shops where a good chunk of Silicon Valley gets financed. It writes pre-seed, seed and Series A checks into companies with at least one Oxford graduate on the founding team. It started life in 2016 as the Oxford Angel Fund and rebranded to Oxonian Ventures in 2024 - "Oxonian" being the formal word for a member of the university, so the entire thesis is baked into the name.
The model has two sides, and both are Oxford graduates. On one side are the founders who need capital. On the other are the roughly 90 accredited investors - alumni themselves - who supply it. The fund sits in the middle, turning a shared quad into a channel that generalist firms cannot easily copy. Founders apply through the fund's Gust pathway; alumni investors join through an interest form. It is, in effect, a matching engine built on a diploma.
The problemTalent that scatters, capital that does not follow
Oxford is one of the most productive research universities on earth. It has spun out hundreds of companies and routinely tops global rankings. But its graduates do not stay put. They leave for London, for Boston, for the Bay Area, and they start companies far from the city where their network began. For an alumnus in Palo Alto with an idea and no Sand Hill Road rolodex, the Oxford connection is real but hard to cash in.
That is the gap Oxonian Ventures works. It gives dispersed Oxford founders a warm door to early capital, and it gives alumni investors a structured way to back people they already have a reason to trust. The fund also leans on a piece of research it likes to cite: founders who share an alma mater with their backers are meaningfully more likely to reach an IPO. Whether or not you buy the exact figure, the logic is intuitive - shared context lowers the cost of trust, and trust is most of what a pre-seed check is buying.
The portfolioOvarian cancer tests to probiotic kombucha
The clearest way to understand the fund is to read its portfolio like a menu. There is AOA Dx, building a liquid-biopsy blood test for the early diagnosis of ovarian cancer. There is Ligo Biosciences, designing enzymes for industry with AI, and ExcepGen, engineering mRNA therapeutics. There is Conductor Quantum, writing software to make quantum computers scale, and Everbloom, working on next-generation alternatives to plastics and fibers. And then, cheerfully, there is Walker Brothers, which makes probiotic-filled kombucha. The only thread connecting a cancer diagnostic to a fermented drink is an Oxford degree - which is precisely the point.
Where the money leans - portfolio by emphasis
Roughly 30% of investments are early-stage life science; the rest spreads across sectors that mirror Oxford's research strengths. Bars are approximate emphasis, not exact allocations.
How it differsA niche so specific it becomes a moat
The obvious question is how a small fund in Palo Alto competes with the giants down the road. The answer is that it does not, really - it competes on access. Sequoia is not systematically calling every Oxford graduate who just left a lab with a company idea. Oxonian Ventures is. Its edge is not a sharper thesis on any single market; it is ownership of a lane - "Oxford alumni startups" - that no generalist wants to carve out and few could reach if they tried.
That focus also shows up in the closest comparisons. University-linked investors such as Oxford Sciences Enterprises back spinouts that come directly out of the university's labs. Oxonian Ventures is different: it is independent, alumni-led, and follows the graduates wherever they land, not the intellectual property that stays behind. It is the diaspora fund, not the campus fund.
The businessHow the fund actually makes money
Structurally, there is nothing exotic here, and that is a compliment. Oxonian Ventures runs a standard closed-end venture fund. It raises committed capital from accredited alumni investors, deploys it as equity into early-stage companies, and aims to return gains when those companies are acquired or go public. The general partners are paid the usual way - management fees to run the fund, carried interest on the upside. The novelty is entirely in the sourcing, not the plumbing.
Exits have started to arrive. DocuVision, an AI redaction startup, was acquired by OneTrust in 2020. Going Merry, which matched students with scholarships, was bought by Earnest in 2021. Rainmakers, a marketplace for salespeople, was acquired by Hirewell in 2022. For a fund that only started writing checks in 2016, a handful of acquisitions is the early evidence that a network can be a strategy and not just a slogan.
The expertiseThe people writing the checks
The fund is led by four general partners, all Oxford alumni. Paula Skokowski (Engineering Science, St. Edmund Hall) co-founded it and doubles as a chief marketing officer in cybersecurity. Neil Wolff (Management Studies, Lincoln College) and Cameron Turner (MBA, Christ Church) round out the founding trio, an engineer, a manager and an operator. In early 2025 the team added serious institutional weight: Heather Preston, a healthcare investor with more than 20 years across NEA, TPG Biotech and JPMorgan Partners, an Oxford medical degree, and board seats at 20-plus companies. Recruiting an investor of that pedigree is the clearest signal yet that the "angel club" era is over.
The timelineFrom angel club to third fund
- 2016Oxford Angel Fund launchesSkokowski, Wolff and Turner start an alumni-led fund backing Oxford-founded companies.
- 2020First exit signalPortfolio company DocuVision is acquired by OneTrust.
- 2021Going Merry acquiredScholarship-matching fintech is bought by Earnest.
- 2024Rebrand and Fund IIIOxford Angel Fund becomes Oxonian Ventures; first close of a $15M third fund in July.
- 2025Heather Preston joinsVeteran healthcare investor comes on as General Partner to lead biotech deals.
The marketWhere it fits
Zoom out and Oxonian Ventures sits in a growing category: the affinity fund, where the shared identity is the sourcing advantage. Others have done it with universities, ethnic communities and professional guilds. Oxonian's version is unusually clean because the affinity is so old and so recognizable - eight centuries of an institution, distilled into deal flow. The bet is that as Oxford keeps producing founders faster than any single campus fund can absorb, a firm designed to catch them anywhere on the map has room to grow.
For a founder, the practical takeaway is direct. If you went to Oxford and you are raising your first real round, there is a fund whose entire job is to find you, understand the shorthand you speak, and put alumni capital behind you. For everyone else, the lesson is worth stealing: the most defensible deal flow might not be a market insight at all. It might be a group you already belong to that nobody has bothered to organize into capital yet.